Treatment with the SQ tree sublingual immunotherapy tablet is safe and well tolerated in real-life.

ABSTRACT:

Background

The SQ tree sublingual immunotherapy (SLIT)-tablet is authorised for treatment of allergic rhinoconjunctivitis with or without asthma in trees of the birch homologous group in 21 European countries. The primary objective of this study was to explore the safety in real-life.

Methods

In a prospective, non-interventional post-authorisation safety study (EUPAS31470), adverse events (AEs) and adverse drug reactions (ADRs) at first administration and follow-up visits, symptoms, medication use, and pollen food syndrome were recorded by physicians in 6 European countries during the first 4-6 months of treatment.

Results

ADRs with the SQ tree SLIT-tablet were reported in 57.7% of 1069 total patients (median age 36.0 years, 53.7% female) during the entire observation

SUBMITTER: Pfaar O 

PROVIDER: S-EPMC11219271 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature